Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 4/20 | 0.41 |
| ▸ | WNT3A | P56704 | 4/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | MET | P08581 | 1/20 | 0.37 |
| ▸ | SCD | O00767 | 1/20 | 0.37 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.37 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.36 |
| ▸ | WDR5 | P61964 | 1/20 | 0.36 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.36 |
| ▸ | BACE1 | P56817 | 1/20 | 0.36 |
| ▸ | ABL1 | P00519 | 1/20 | 0.36 |
| ▸ | BCR | P11274 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6846512 | 0.90 | PTPN11 (0.40) | TRPV1ACHEMETSCDSCD5 | |
| SCHEMBL6841382 | 0.88 | WNT3A (0.41) | WNT3AACHEMETSCDSCD5 | |
| SCHEMBL6846894 | 0.85 | ABL1 (0.43) | TRPV1WNT3AALKWDR5UCHL1 | |
| SCHEMBL7228820 | 0.85 | WNT3A (0.43) | WNT3AACHESCDSCD5 | |
| SCHEMBL7228824 | 0.85 | WNT3A (0.42) | WNT3AACHESCDSCD5 | |
| SCHEMBL6844794 | 0.84 | MAP3K20 (0.39) | TRPV1ACHEMETSCDSCD5 | |
| SCHEMBL6848352 | 0.84 | ALDH1A1 (0.40) | TRPV1METSCDSCD5ALK | |
| SCHEMBL6846439 | 0.78 | BACE1 (0.43) | TRPV1BACE1 | |
| SCHEMBL6846514 | 0.78 | TSHR (0.42) | ACHEMETSCDSCD5BACE1 | |
| SCHEMBL6846837 | 0.76 | MAP3K20 (0.36) | TRPV1MET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040092747-A1 | Amide compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use | BENDER STEVEN LEE (US) | 2004-05-13 | — | — | US | disclosed |
| US-6635641-B2 | For treating cancer and other disease states associated with unwanted angiogenesis and/or cellular proliferation such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, psoriasis | AGOURON PHARMACEUTICALS, INC. | 2003-10-21 | — | — | US | disclosed |
| EP-1252146-A1 | AMIDE COMPOUNDS FOR INHIBITING PROTEIN KINASES | AGOURON PHARMACEUTICALS, INC. (US) | 2002-10-30 | — | — | EP | disclosed |
| US-20020103203-A1 | Amide compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use | AGOURON PHARMACEUTICALS, INC. | 2002-08-01 | — | — | US | disclosed |
| WO-2001053274-A1 | AMIDE COMPOUNDS FOR INHIBITING PROTEIN KINASES | AGOURON PHARMACEUTICALS, INC. (US) | 2001-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092747-A1 | Amide compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use | BRAF, CNKSR1, UACA | TRPV1 2172/4885WNT3A 4092/4885ACHE 2730/4885 |
| US-20020103203-A1 | Amide compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use | BRAF, CNKSR1, UACA | TRPV1 2172/4885WNT3A 4092/4885ACHE 2730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.